Trial Search Results

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Boston Children's Hospital

Collaborator: Terrana ITP Research Fund

Stanford Investigator(s):


  • Drug: Second Line ITP agents


Inclusion Criteria:

   - Immune Thrombocytopenia or Evans Syndrome

   - Ages > 12 months to <18 years

   - Starting a new second line therapy as defined as any therapy except IVIG, steroids,
   anti-D globulin, or aminocaproic acid

   - Starting a single agent/monotherapy

Exclusion Criteria:

   - Evans Syndrome with a history of or current evidence of autoimmune hemolytic anemia

   - Unwillingness to be followed for 1 year

   - Physician providing care is unwilling to participate

   - Patient is starting multiple second line agents simultaneously

Ages Eligible for Study

1 Year - 18 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Michael Jeng
Not Recruiting